JP2005511002A - 骨量変調のトランスジェニック動物モデル - Google Patents

骨量変調のトランスジェニック動物モデル Download PDF

Info

Publication number
JP2005511002A
JP2005511002A JP2002589632A JP2002589632A JP2005511002A JP 2005511002 A JP2005511002 A JP 2005511002A JP 2002589632 A JP2002589632 A JP 2002589632A JP 2002589632 A JP2002589632 A JP 2002589632A JP 2005511002 A JP2005511002 A JP 2005511002A
Authority
JP
Japan
Prior art keywords
gene
bone
hbm
lrp5
mouse
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2002589632A
Other languages
English (en)
Japanese (ja)
Inventor
バビィ，フィリップ
ベックス，フレデリック・ジェイムズ，ザ・サード
ボーディン，ピーター・ヴァン・ネスト
アスキュー，ロジャー・ジー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of JP2005511002A publication Critical patent/JP2005511002A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/50—Amphibians, e.g. Xenopus
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/60—Vectors containing traps for, e.g. exons, promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
    • C12N2840/105—Vectors comprising a special translation-regulating system regulates levels of translation enhancing translation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Husbandry (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
JP2002589632A 2001-05-11 2002-05-13 骨量変調のトランスジェニック動物モデル Withdrawn JP2005511002A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29007101P 2001-05-11 2001-05-11
US29131101P 2001-05-17 2001-05-17
US35305802P 2002-02-01 2002-02-01
US36129302P 2002-03-04 2002-03-04
PCT/US2002/014876 WO2002092764A2 (en) 2001-05-11 2002-05-13 Transgenic animal model of bone mass modulation

Publications (1)

Publication Number Publication Date
JP2005511002A true JP2005511002A (ja) 2005-04-28

Family

ID=27501520

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2002589632A Withdrawn JP2005511002A (ja) 2001-05-11 2002-05-13 骨量変調のトランスジェニック動物モデル
JP2002588919A Withdrawn JP2004537289A (ja) 2001-05-11 2002-05-13 骨量および脂質レベルを調整するｈｂｍ変異型
JP2010146427A Pending JP2011004744A (ja) 2001-05-11 2010-06-28 骨量および脂質レベルを調整するｈｂｍ変異型

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2002588919A Withdrawn JP2004537289A (ja) 2001-05-11 2002-05-13 骨量および脂質レベルを調整するｈｂｍ変異型
JP2010146427A Pending JP2011004744A (ja) 2001-05-11 2010-06-28 骨量および脂質レベルを調整するｈｂｍ変異型

Country Status (7)

Country Link
US (2) US7416849B2 (enExample)
EP (2) EP1401269A4 (enExample)
JP (3) JP2005511002A (enExample)
AU (2) AU2002308681A1 (enExample)
BR (2) BR0209563A (enExample)
CA (2) CA2446821A1 (enExample)
WO (2) WO2002092000A2 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6780609B1 (en) * 1998-10-23 2004-08-24 Genome Therapeutics Corporation High bone mass gene of 1.1q13.3
US6770461B1 (en) 1998-10-23 2004-08-03 Genome Therapeutics Corporation High bone mass gene of 11q13.3
IL152654A0 (en) * 2000-05-26 2003-06-24 Genome Therapeutics Corp Regulating lipid levels via the zmaxi or hbm gene
US7514594B2 (en) 2001-05-11 2009-04-07 Wyeth Transgenic animal model of bone mass modulation
BR0209563A (pt) 2001-05-11 2004-12-07 Genome Theraupeutics Corp ácido nucleico, polipeptìdeo, vetor, célula, anticorpo, métodos de diagnosticar um fenótipo e um paciente como expressando um ácido nucleico e de identificar agentes que modulam a atividade de um ácido nucleico e de uma proteìna e lrp5, lrp6, ou hbm e compostos que modulam a interação de dkk com o caminho de sinalização wnt, composição para modular a massa óssea e/ou os nìveis de lipìdeo em um paciente, animal transgênico, embrião e modelo de animal, e, agente
CA2446582A1 (en) * 2001-05-17 2002-11-21 Genome Therapeutics Corporation Reagents and methods for modulating dkk-mediated interactions
US20040038860A1 (en) 2002-05-17 2004-02-26 Allen Kristina M. Reagents and methods for modulating dkk-mediated interactions
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
US7223393B2 (en) 2003-02-07 2007-05-29 Pdl Biopharma, Inc Amphiregulin antibodies and their use to treat cancer and psoriasis
FR2856410B1 (fr) * 2003-06-20 2007-06-15 Integragen Sa Methodes de preparation de puces genetiques et utilisations
US20080227734A1 (en) * 2003-11-24 2008-09-18 Gunnar Westin Mutant Lrp5/6 Wnt-Signaling Receptors in Cancer Diagnosis, Prognosis, and Treatment
EP1747462A2 (en) * 2004-04-27 2007-01-31 Galapagos N.V. Methods, agents, and compound screening assays for inducing differentiation of undifferentiated mammalian cells into osteoblasts
CA2566256C (en) * 2004-05-07 2015-07-07 Applera Corporation Genetic polymorphisms associated with liver fibrosis methods of detection and uses thereof
JP2008507294A (ja) 2004-07-26 2008-03-13 ダウ グローバル テクノロジーズ インコーポレイティド 菌株遺伝子操作による改善されたタンパク質発現のための方法
ES2414460T3 (es) 2004-08-04 2013-07-19 Amgen Inc. Anticuerpos para Dkk-1
US7771937B2 (en) * 2005-05-20 2010-08-10 University Of Washington Methods for predicting late onset Alzheimer disease in an individual
US20080293053A1 (en) * 2006-12-28 2008-11-27 The Regents Of The University Of Michigan shRNA Materials and Methods of Using Same for Inhibition of DKK-1
FI3345607T3 (fi) 2006-12-29 2022-11-30 Menetelmiä luun kasvun muuttamiseksi antamalla SOST- tai WISE-antagonistia tai antagonistia
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
EP2615172A1 (en) 2007-04-27 2013-07-17 Pfenex Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
ES2560532T3 (es) * 2007-11-02 2016-02-19 Novartis Ag Moléculas y métodos de modulación de la proteína 6 relacionada con el receptor de lipoproteína de baja densidad (LRP6)
US8716243B2 (en) * 2008-05-28 2014-05-06 St. Jude Childen's Research Hospital Methods of effecting Wnt signaling through Dkk structural analysis
WO2009146956A1 (en) * 2008-06-03 2009-12-10 Universite De Liege Biomarker for osteoarthritis and/or other ageing-related diseases, and use thereof
BR112012020257A8 (pt) * 2010-02-11 2018-02-14 Recombinetics Inc métodos e aparelhos para produzir artiodátilos transgênicos
SG184033A1 (en) 2010-03-24 2012-10-30 Genentech Inc Anti-lrp6 antibodies
ES2659406T3 (es) 2010-05-06 2018-03-15 Novartis Ag Composiciones y procedimientos de uso para anticuerpos terapéuticos contra la proteína 6 relacionada con las lipoproteínas de baja densidad (LRP6)
US9290573B2 (en) 2010-05-06 2016-03-22 Novartis Ag Therapeutic low density lipoprotein-related protein 6 (LRP6) multivalent antibodies
US10920242B2 (en) 2011-02-25 2021-02-16 Recombinetics, Inc. Non-meiotic allele introgression
MX2014005411A (es) 2011-11-04 2015-02-12 Novartis Ag Construcciones prolongadas de la vida media de la proteina relacionada con lipoproteina de baja densidad 6 (lrp6).
CN104540382A (zh) * 2012-06-12 2015-04-22 弗·哈夫曼-拉罗切有限公司 用于产生条件性敲除等位基因的方法和组合物
US8959241B2 (en) * 2012-07-23 2015-02-17 Adobe Systems Incorporated Method and apparatus for performing server-side splicing for live streaming media
US9932588B2 (en) 2013-11-15 2018-04-03 Northwestern University Inhibition of oxidative stress in atrial fibrillation
US9732345B2 (en) 2013-12-09 2017-08-15 Baylor College Of Medicine Hippo and dystrophin complex signaling in cardiomyocyte renewal
TW201710503A (zh) 2015-06-12 2017-03-16 長庚醫療財團法人林口長庚紀念醫院 新穎多核苷酸、載體、醫藥組成物以及其用途
US20180037909A1 (en) 2016-08-04 2018-02-08 Chang Gung Memorial Hospital, Linkou Modified cancer cell lines and uses thereof
US20190218306A1 (en) * 2018-01-18 2019-07-18 Nalini M. Rajamannan Method of inhibiting ectopic calcification

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283173A (en) * 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
AU7392696A (en) 1995-10-04 1997-04-28 Warner-Lambert Company Compounds, compositions and methods for inhibiting the binding of proteins containing an sh2 domain to cognate phosphorylated proteins
US5691153A (en) * 1996-09-06 1997-11-25 Creighton University Genetic markers to detect high bone mass
EP0988379B1 (en) * 1997-04-15 2007-04-11 The Wellcome Trust Limited as Trustee to the Wellcome Trust Ldl-receptor
US6555654B1 (en) * 1997-04-15 2003-04-29 The Wellcome Trust Limited As Trustee For The Wellcome Trust LDL-receptor
BE1011331A6 (fr) 1997-08-20 1999-07-06 Univ Catholique De Louvain Hal Polypeptide associe au peroxysome, sequence nucleotidique encodant ledit polypeptide et leur utilisation dans le diagnostic et/ou le traitement de maladies ou de lesions pulmonaires.
EP1064289A1 (en) 1998-03-18 2001-01-03 Ariad Pharmaceuticals, Inc. Heterocyclic signal transduction inhibitors, compositions containing them
AU4023200A (en) 1999-03-26 2000-10-16 Human Genome Sciences, Inc. 50 human secreted proteins
IL151904A0 (en) * 2000-04-05 2003-04-10 Genome Therapeutics Corp THE HIGH BONE MASS GENE OF 11q13.3
IL152654A0 (en) 2000-05-26 2003-06-24 Genome Therapeutics Corp Regulating lipid levels via the zmaxi or hbm gene
JP2004517605A (ja) * 2000-06-21 2004-06-17 デルタジェン　インコーポレイテッド 標的化遺伝子破壊を含むトランスジェニックマウス
EP1313753A4 (en) 2000-08-18 2004-09-15 Proskelia REGULATORY GENE AND SYSTEM FOR USE IN THE DIAGNOSIS AND TREATMENT OF OSTEOPOROSIS
BR0209563A (pt) 2001-05-11 2004-12-07 Genome Theraupeutics Corp ácido nucleico, polipeptìdeo, vetor, célula, anticorpo, métodos de diagnosticar um fenótipo e um paciente como expressando um ácido nucleico e de identificar agentes que modulam a atividade de um ácido nucleico e de uma proteìna e lrp5, lrp6, ou hbm e compostos que modulam a interação de dkk com o caminho de sinalização wnt, composição para modular a massa óssea e/ou os nìveis de lipìdeo em um paciente, animal transgênico, embrião e modelo de animal, e, agente
US8637506B2 (en) * 2003-09-22 2014-01-28 Enzo Biochem, Inc. Compositions and methods for bone formation and remodeling
DE102007020878B4 (de) 2007-05-04 2020-06-18 Dr. Ing. H.C. F. Porsche Aktiengesellschaft Verfahren zur Prüfung von Umströmungsgeräuschen

Also Published As

Publication number Publication date
AU2002316095A1 (en) 2002-11-25
BR0209564A (pt) 2004-10-26
US20050070699A1 (en) 2005-03-31
JP2011004744A (ja) 2011-01-13
CA2446821A1 (en) 2002-11-21
WO2002092764A2 (en) 2002-11-21
EP1401269A2 (en) 2004-03-31
AU2002308681A1 (en) 2002-11-25
EP1483288A2 (en) 2004-12-08
WO2002092000A3 (en) 2004-10-07
US20090136507A1 (en) 2009-05-28
CA2446859A1 (en) 2002-11-21
EP1401269A4 (en) 2005-09-28
JP2004537289A (ja) 2004-12-16
US7416849B2 (en) 2008-08-26
BR0209563A (pt) 2004-12-07
EP1483288A4 (en) 2005-09-21
WO2002092000A2 (en) 2002-11-21
WO2002092764A3 (en) 2003-12-24

Similar Documents

Publication Publication Date Title
JP2005511002A (ja) 骨量変調のトランスジェニック動物モデル
US20090023905A1 (en) Transgenic animal model of bone mass modulation
CN100381570C (zh) 滑膜细胞蛋白质
AU2007200880A1 (en) Regulating lipid levels via the ZMAX1 or HBM gene
JP2000510333A (ja) 因子活性を調節することによりｔ細胞サブセットを制御するための方法及び組成物
AU2000256269B2 (en) The high bone mass gene of 11q13.3
US7285400B2 (en) High bone mass gene of 11q13.3
US20040221326A1 (en) Transgenic animal model of bone mass modulation
EP1964921A2 (en) The high bone mass gene of 11q13.3
US20030219793A1 (en) High bone mass gene of 11q13.3
AU2001269712B2 (en) Regulating lipid levels via the ZMAXI or HBM gene
AU2007200352A1 (en) The high bone mass gene of 11q13.3
JP2006506067A (ja) 新規ｐｔｈ反応性遺伝子
US20060079674A1 (en) Contraceptive targets
Carulli et al. Regulating Lipid Levels Via the ZMAX1 or HBM Gene
AU2001269712A1 (en) Regulating lipid levels via the ZMAXI or HBM gene
AU2001269712A2 (en) Regulating lipid levels via the ZMAXI or HBM gene
CA2483323A1 (en) Contraceptive targets

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050510

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20060428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20060428